Metabolic Biomarkers Guide
Your lab results tell a deeper story than any single number. This guide explains every metabolic test your PYW physician monitors, what it actually measures, what optimal ranges look like for a wellness-focused patient, and what your program is actively doing to move each marker in the right direction.
Fasting Blood Glucose
Fasting glucose measures the concentration of sugar circulating in your blood after a minimum of eight hours without food. It reflects your body's baseline ability to regulate blood sugar using insulin — and it is one of the most widely tested metabolic markers because it correlates with insulin resistance, cardiovascular risk, metabolic syndrome, cognitive function, and inflammatory load. When this baseline is elevated, it means insulin is no longer doing its job efficiently even between meals.
Why "fasting" matters: After eating, glucose rises and insulin is released to manage it. Eight hours without food removes this variable, giving your physician a picture of hormonal glucose regulation at rest. A high fasting glucose means that even without dietary input, the system is struggling to keep sugar out of circulation.
| Category | Range | What It Means |
|---|---|---|
| Wellness-Optimal | 72–85 mg/dL | Maximum insulin sensitivity. Lowest baseline inflammatory load. The target on a PYW program. |
| Standard Normal | 86–99 mg/dL | No clinical diagnosis. Review in context of fasting insulin — 95 mg/dL with elevated insulin signals early resistance the glucose number alone hides. |
| Prediabetes | 100–125 mg/dL | Impaired fasting glucose. Significant but reversible with consistent program adherence. Protocol action required. |
| Diabetes (diagnostic) | ≥ 126 mg/dL | Meets Type 2 diabetes criteria on two separate occasions. Requires active physician management. |
Elevated fasting glucose almost always indicates developing insulin resistance — your cells are becoming less responsive to insulin's signal to absorb glucose. This develops over years of high refined-carbohydrate intake, poor sleep, chronic stress, and insufficient movement. It does not reverse overnight, but it does reverse. Most members see fasting glucose trending downward within 8–12 weeks of consistent program adherence.
Critical context: Never read fasting glucose alone. A result of 96 mg/dL with normal fasting insulin looks completely different from 96 mg/dL with elevated fasting insulin — the latter means your pancreas is already working overtime to maintain what appears to be a normal reading.
- Metabolic therapy directly improves insulin sensitivity and reduces the liver's overnight glucose output — the two primary drivers of fasting glucose.
- Protein-first eating at every meal slows gastric emptying and blunts the post-meal glucose spikes that cumulatively elevate fasting baseline over time.
- Resistance training (Exercise Programs 1–3) increases skeletal muscle glucose uptake capacity — the body's primary non-insulin pathway for glucose clearance.
- Sleep optimization improves overnight insulin sensitivity. Members reaching 7–8 hours consistently see fasting glucose improve faster than those who do not.
- Reducing refined carbohydrates lowers the demand placed on insulin throughout the day, directly reducing the compensatory elevation that shows in fasting results.
HbA1c — Glycated Hemoglobin
HbA1c measures the percentage of hemoglobin molecules in your red blood cells that have glucose permanently bonded to them — a process called glycation. Because red blood cells live approximately 90–120 days, HbA1c reflects a rolling average of your blood glucose over the entire prior three months. It is the most clinically meaningful single-number summary of your glycemic environment over time.
Why it matters beyond diabetes screening: HbA1c is one of the strongest predictors of cardiovascular risk, cognitive aging, and long-term metabolic trajectory — even when values are well below the diabetic threshold. The NEJM cardiovascular outcomes trial reviewed in our research section documented a 28% improvement in HbA1c among participants in sustained metabolic programs — one of the most significant findings in the entire dataset.
| Category | Range | What It Means |
|---|---|---|
| Wellness-Optimal | 4.6–5.2% | Excellent glycemic control. Lowest cardiovascular and inflammatory risk profile. The PYW program target. |
| Functional Good | 5.3–5.6% | Within functional optimal. Watch trend direction — is it improving or drifting upward quarter over quarter? |
| Prediabetes | 5.7–6.4% | Elevated risk. Significant but reversible. Every 1% reduction in HbA1c is associated with a meaningful reduction in cardiovascular event risk. |
| Diabetes (diagnostic) | ≥ 6.5% | Meets Type 2 diabetes diagnostic criteria. Physician management required. Reversible with sustained program adherence in many cases. |
HbA1c is most powerful as a trend marker, not a one-time snapshot. A single HbA1c of 5.8% tells your physician you have room to improve. Three quarterly results trending 6.1% → 5.9% → 5.7% tells them your program is working at the cellular level — even if the scale has slowed during that same period.
This is one of the most important reasons your PYW physician tracks labs quarterly rather than annually. Annual testing captures status. Quarterly testing captures trajectory — and trajectory is what determines long-term outcomes.
HbA1c has a significant limitation: it can read as completely normal while insulin resistance is already well established. A patient whose pancreas is overproducing insulin to maintain a normal glucose average will show a normal HbA1c — but is metabolically stressed in a way invisible without fasting insulin testing.
Research found 82% of patients with normal glucose and normal HbA1c showed signs of insulin resistance on comprehensive testing. This is exactly why your PYW panel includes fasting insulin — to catch what HbA1c alone cannot see.
Fasting Insulin — Why This Is the Test Most Physicians Skip
Fasting insulin measures the amount of insulin circulating in your blood after an overnight fast. When cells become resistant to insulin's signal, the pancreas compensates by producing more insulin to achieve the same result. Elevated fasting insulin is the earliest detectable sign of metabolic dysfunction — appearing years or even decades before fasting glucose or HbA1c rise into abnormal ranges.
Despite this, fasting insulin is absent from most standard lab panels in conventional medicine. The standard printed reference range (typically 2–25 μIU/mL) is far too wide to be clinically useful for wellness-focused patients. Your PYW quarterly panel includes it specifically because it reveals dysfunction when intervention is most effective — before a diagnosis is necessary.
| Category | Range | What It Means |
|---|---|---|
| Wellness-Optimal | 2–5 μIU/mL | Highly insulin-sensitive. Cells responding efficiently. Lowest metabolic disease risk. The PYW target. |
| Functional Good | 6–10 μIU/mL | Reasonable range. Room for improvement. Monitor trend at each quarterly panel. |
| Early Warning | 11–20 μIU/mL | Early-to-moderate insulin resistance. Glucose and HbA1c may still look normal — the pancreas is compensating. Protocol action warranted. |
| Significant Resistance | > 20 μIU/mL | Clear insulin resistance regardless of glucose reading. Physician review and protocol adjustment required. |
Combining Insulin and Glucose into One Score
Your fasting insulin and fasting glucose results can be combined into a single calculated score called HOMA-IR (Homeostatic Model Assessment of Insulin Resistance). It is the most validated tool for assessing insulin sensitivity from routine lab values.
Formula: (Fasting Insulin × Fasting Glucose) ÷ 405
- HOMA-IR below 1.5 — wellness-optimal. Your cells are highly responsive to insulin.
- HOMA-IR 1.5–2.0 — functional range. The US population median is approximately 2.2.
- HOMA-IR 2.0–2.9 — early insulin resistance. Program intervention is recommended.
- HOMA-IR 3.0 and above — significant insulin resistance. Direct physician review warranted.
- Use the HOMA-IR Calculator tab to enter your numbers and get a personalized interpretation.
Fasting insulin is one of the fastest-moving biomarkers on a well-managed program. It often improves before HbA1c or fasting glucose, making it an excellent early signal that your interventions are working.
- Reducing refined carbohydrates and added sugars directly lowers the demand on the pancreas throughout the day — reducing baseline insulin production.
- Resistance training increases insulin receptor sensitivity in skeletal muscle — the body's largest glucose-clearing tissue.
- Sleep optimization restores overnight insulin sensitivity. Even one week of shortened sleep raises fasting insulin measurably in research studies.
- Metabolic therapy supports insulin sensitivity through hormonal and appetite-regulation pathways that complement dietary and exercise interventions.
- Most members with elevated fasting insulin see meaningful improvement within 8–12 weeks of consistent program adherence.
Insulin resistance is not a single disease — it is the metabolic root of Type 2 diabetes, cardiovascular disease, fatty liver disease, polycystic ovarian syndrome, and metabolic syndrome. Addressing it early, when fasting insulin is elevated but glucose still looks normal, is when intervention is most effective and results most durable.
- Chronically elevated insulin promotes abdominal fat storage and blocks fat oxidation — directly opposing your program's fat loss objectives.
- High insulin raises triglycerides and lowers HDL — producing the lipid pattern most strongly associated with cardiovascular disease.
- Insulin resistance impairs growth hormone release during sleep — reducing the overnight repair benefit your program's protocols depend on.
- Every quarterly panel showing falling fasting insulin confirms your program is addressing the root driver, not just managing downstream symptoms.
The Complete Lipid Panel — Four Numbers That Work as a System
Your lipid panel measures four distinct components of the fats circulating in your blood. Each tells a different story about cardiovascular risk and metabolic function. The most important insight in modern lipid interpretation is that these numbers must be read together — no single value tells the complete picture, and the relationships between markers are often more informative than any individual result.
LDL carries cholesterol through the bloodstream to cells that need it. The clinical concern is not LDL itself but a specific type called small, dense LDL particles — small enough to penetrate arterial walls and form plaque. A standard panel reports total LDL cholesterol concentration but does not distinguish between large, buoyant (lower risk) and small, dense (higher risk) particles. This is why LDL-C alone is an incomplete cardiovascular risk marker — especially when metabolic syndrome is present.
| Category | Range | Clinical Meaning |
|---|---|---|
| Optimal | < 100 mg/dL | Standard optimal. Always read alongside TG/HDL ratio for full picture of particle quality. |
| Near Optimal | 100–129 mg/dL | Acceptable for lower-risk individuals. Review in full context of other markers. |
| Borderline High | 130–159 mg/dL | Elevated risk — especially significant alongside high triglycerides. |
| High | ≥ 160 mg/dL | Requires physician review and full cardiovascular risk assessment. |
HDL performs reverse cholesterol transport — pulling cholesterol out of arterial walls and carrying it to the liver for disposal. Higher HDL is consistently protective against cardiovascular disease. HDL is also one of the most sensitive early markers of insulin resistance: low HDL almost universally co-occurs with elevated triglycerides and impaired glucose metabolism, forming the classic dyslipidemia pattern of metabolic syndrome.
| Category | Range | Clinical Meaning |
|---|---|---|
| Wellness-Optimal | 60–90+ mg/dL | Highly cardioprotective. Target equally for men and women on a wellness program. |
| Adequate (Women) | 50–59 mg/dL | Standard normal. Improve with resistance training, cardiovascular exercise, omega-3 intake. |
| Adequate (Men) | 40–59 mg/dL | Standard normal. Resistance and aerobic exercise both raise HDL meaningfully over 8–12 weeks. |
| Low (Elevated Risk) | < 50 (W) / < 40 (M) | Elevated cardiovascular risk. Almost always paired with high triglycerides and insulin resistance. |
Triglycerides are the body's primary energy storage form from excess calories — particularly excess carbohydrates. They are the single most metabolically responsive marker on your lipid panel: they can drop dramatically within weeks of reducing refined carbohydrates, improving sleep, and beginning structured exercise. They are also one of the strongest indirect markers of insulin resistance, because insulin resistance directly impairs the liver's ability to clear triglycerides from circulation.
| Category | Range | Clinical Meaning |
|---|---|---|
| Wellness-Optimal | < 70 mg/dL | Excellent metabolic flexibility and insulin sensitivity. The PYW program target. |
| Good | 70–100 mg/dL | Functional range with room to improve. Responsive to dietary carbohydrate reduction. |
| Borderline | 101–149 mg/dL | Standard labs may call this "normal." It is not optimal for a wellness-focused patient. Address with nutrition protocol. |
| High | ≥ 150 mg/dL | Significant concern. Strong signal of insulin resistance. Requires direct protocol action. |
The TG/HDL ratio (triglycerides divided by HDL) is one of the most informative calculations available from a standard lipid panel — yet it is almost never automatically reported. A 2025 study found it achieved an AUC of 0.88 in discriminating insulin resistance, outperforming either marker alone. It is also the best available surrogate for small, dense LDL particle concentration — the truly atherogenic LDL that standard LDL-C does not reveal.
Calculate yours: Divide your triglycerides by your HDL. Example: 118 ÷ 52 = 2.27 (warning range)
| Score | Category | What It Means |
|---|---|---|
| < 1.0 | Optimal | Highly insulin-sensitive. Minimal small dense LDL. Lowest cardiovascular risk pattern. |
| 1.0–1.9 | Good | Functional range. Insulin-sensitive with room to improve. |
| 2.0–2.9 | Warning | Early insulin resistance pattern. Responds well to reduced refined carbs and exercise. |
| ≥ 3.0 | Concern | Strong insulin resistance and cardiovascular risk signal. Direct protocol review required. |
Apolipoprotein B (ApoB) is a protein present on the surface of every atherogenic lipoprotein particle — one molecule per particle. Your ApoB level is essentially a count of your total atherogenic particle number, regardless of how much cholesterol each particle carries. It is a more accurate cardiovascular risk measure than standard LDL-C, particularly when metabolic syndrome is present and LDL-C appears normal while particle count is elevated.
- Wellness-optimal ApoB: below 80 mg/dL
- Standard acceptable: below 100 mg/dL
- Ask your physician to add ApoB if your triglycerides are elevated while LDL-C looks normal — this pattern often hides a dangerous particle burden
- If ApoB is unavailable, non-HDL cholesterol (Total Cholesterol minus HDL) is the next best approximation — it captures all atherogenic fractions in one calculation
Your HOMA-IR Calculator
HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is the most widely validated insulin resistance scoring tool available from routine lab values. It uses your fasting insulin and fasting glucose together to calculate a single score that reflects how well your cells are responding to insulin. Enter your most recent fasting values from your PYW lab report below.
Formula: (Fasting Insulin μIU/mL × Fasting Glucose mg/dL) ÷ 405
Both values must be from a fasted blood draw (8+ hours, no food or caloric beverages). Find them on your PYW quarterly lab report.
| Score | Category | What It Means for Your Program |
|---|---|---|
| 0.5–1.5 | Wellness-Optimal | Highly insulin-sensitive. Your cells are responding efficiently. Continue your current protocols. |
| 1.5–2.0 | Functional Range | US population median is approximately 2.2. You are in a reasonable functional range with meaningful room to improve toward optimal. |
| 2.0–2.9 | Early Resistance | Early insulin resistance indicated. Discuss nutrition protocol, sleep quality, and resistance training consistency at your next PYW check-in. |
| ≥ 3.0 | Significant Resistance | Warrants a direct physician conversation. Not a failure — a signal that a protocol review is needed. Call (912) 355-3185. |
| Biomarker | Wellness-Optimal | Standard Reference | Key Note |
|---|---|---|---|
| Fasting Glucose | 72–85 mg/dL | 70–99 mg/dL | Always test alongside fasting insulin. A glucose of 95 mg/dL with elevated insulin is a very different clinical picture than 95 with normal insulin. |
| HbA1c | 4.6–5.2% | < 5.7% | Track trend direction quarterly. Even "normal" HbA1c can hide insulin resistance without fasting insulin testing. |
| Fasting Insulin | 2–5 μIU/mL | 2–25 μIU/mL | Standard range is far too wide. Anything above 10 μIU/mL warrants attention on a wellness program even if labeled "normal." |
| HOMA-IR | 0.5–1.5 | < 2.5 (NHANES) | Formula: (Insulin × Glucose) ÷ 405. Most meaningful insulin resistance composite. Use the Calculator tab above. |
| LDL Cholesterol | < 100 mg/dL | < 130 mg/dL | Interpret alongside TG/HDL ratio. May rise transiently during rapid fat loss — this is normal and temporary. |
| HDL Cholesterol | 60–90+ mg/dL | > 50 (W) / > 40 (M) | Higher is always better. Best improved by resistance training, aerobic exercise, and omega-3 intake. |
| Triglycerides | < 70 mg/dL | < 150 mg/dL | Most responsive marker. Falls quickly with reduced refined carbs. Standard "normal" of 150 mg/dL is far above wellness-optimal. |
| TG ÷ HDL Ratio | < 1.0 | Not typically reported | Calculate yourself. Best surrogate for small dense LDL and insulin resistance from a standard panel. |
| ApoB | < 80 mg/dL | < 100 mg/dL | Ask your physician to add this. More accurate than LDL-C for true atherogenic risk. If unavailable, use non-HDL cholesterol. |
The Patterns That Matter Most
No single biomarker tells the complete story. The most important skill in reading your results is recognizing patterns — because patterns reveal the underlying mechanism, not just a downstream number.
- Elevated fasting insulin + normal glucose + normal HbA1c: Early insulin resistance. The pancreas is compensating successfully — for now. This is the optimal time to intervene. Invisible without a fasting insulin test.
- Elevated triglycerides + low HDL + elevated fasting insulin: The classic insulin resistance lipid pattern. Present before diabetes is diagnosed in most cases. Responds rapidly to reduced refined carbohydrates.
- Falling triglycerides + rising HDL across consecutive panels: One of the clearest signals of improving insulin sensitivity. Often visible within the first two quarterly panels on an active program.
- Falling HbA1c + falling fasting insulin + falling HOMA-IR together: The metabolic improvement trifecta. When all three trend down, your program is working at the cellular level regardless of what the scale shows that week.
- TG/HDL ratio above 2.0 with normal LDL-C: Your standard lipid panel looks fine, but small dense LDL is elevated. This pattern is responsible for cardiovascular events in patients who were told their cholesterol was normal. ApoB testing confirms true risk.